EUVIMEDEUVIMED entdecken
Crossref

332 Trends in Prescribing and Costs of Topical Ruxolitinib Among U.S. Dermatologists

Joshua Kent, Gabriel Santos Malave, Yoni Sacknovitz, Larisa Geskin

Journal of Investigative Dermatology · 2025-11 · 145 (11) · e84

DOI: 10.1016/j.jid.2025.09.334 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Investigative Dermatology, 2025-11. Verfasst von Joshua Kent und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Kent, J., Malave, G. S., Sacknovitz, Y., & Geskin, L. (2025). 332 Trends in Prescribing and Costs of Topical Ruxolitinib Among U.S. Dermatologists. Journal of Investigative Dermatology, 145(11), e84. https://doi.org/10.1016/j.jid.2025.09.334

Vancouver

Kent J, Malave GS, Sacknovitz Y, Geskin L. 332 Trends in Prescribing and Costs of Topical Ruxolitinib Among U.S. Dermatologists. Journal of Investigative Dermatology. 2025;145(11):e84. doi:10.1016/j.jid.2025.09.334

BibTeX
@article{Kent2025,
  author = {Kent, Joshua and Malave, Gabriel Santos and Sacknovitz, Yoni and Geskin, Larisa},
  title = {332 Trends in Prescribing and Costs of Topical Ruxolitinib Among U.S. Dermatologists},
  journal = {Journal of Investigative Dermatology},
  year = {2025},
  volume = {145},
  number = {11},
  pages = {e84},
  doi = {10.1016/j.jid.2025.09.334}
}
Kostenlos starten →